160 related articles for article (PubMed ID: 22426036)
1. Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population.
Salameh G; Al Hadidi K; El Khateeb M
Environ Toxicol Pharmacol; 2012 Jul; 34(1):23-33. PubMed ID: 22426036
[TBL] [Abstract][Full Text] [Related]
2. Frequencies of four genetic polymorphisms in the CYP1A2 gene in Turkish population.
Bilgen T; Tosun O; Luleci G; Keser I
Genetika; 2008 Aug; 44(8):1133-6. PubMed ID: 18825963
[TBL] [Abstract][Full Text] [Related]
3. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
[TBL] [Abstract][Full Text] [Related]
4. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; Endo N; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2003 Mar; 55(3):321-4. PubMed ID: 12630986
[TBL] [Abstract][Full Text] [Related]
5. Genotype and allele frequencies of polymorphic cytochromes P450 CYP1A2 and CYP2E1 in Mexicans.
Mendoza-Cantú A; Castorena-Torres F; Bermudez M; Martínez-Hernández R; Ortega A; Salinas JE; Albores A
Cell Biochem Funct; 2004; 22(1):29-34. PubMed ID: 14695651
[TBL] [Abstract][Full Text] [Related]
6. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects.
Hu M; Yang YL; Fok BS; Chan SW; Chu TT; Poon EW; Yin OQ; Lee VH; Tomlinson B
Drug Metabol Drug Interact; 2012 Jan; 27(1):33-9. PubMed ID: 22718623
[TBL] [Abstract][Full Text] [Related]
7. Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.
Kohlrausch FB; Carracedo Á; Hutz MH
Mol Biol Rep; 2014 Mar; 41(3):1453-60. PubMed ID: 24443221
[TBL] [Abstract][Full Text] [Related]
8. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
9. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
[TBL] [Abstract][Full Text] [Related]
10. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.
Canonico M; Bouaziz E; Carcaillon L; Verstuyft C; Guiochon-Mantel A; Becquemont L; Scarabin PY;
J Clin Endocrinol Metab; 2008 Aug; 93(8):3082-7. PubMed ID: 18628519
[TBL] [Abstract][Full Text] [Related]
11. Allele and genotype frequencies of CYP3A4, CYP3A5, CYP3A7, and GSTP1 gene polymorphisms among mainland Tibetan, Mongolian, Uyghur, and Han Chinese populations.
Qi G; Han C; Zhou Y; Wang X
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):219-227. PubMed ID: 34689350
[TBL] [Abstract][Full Text] [Related]
12. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms.
Aquilante CL; Langaee TY; Anderson PL; Zineh I; Fletcher CV
Clin Chim Acta; 2006 Oct; 372(1-2):195-8. PubMed ID: 16701601
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.
Krishnakumar D; Gurusamy U; Dhandapani K; Surendiran A; Baghel R; Kukreti R; Gangadhar R; Prayaga U; Manjunath S; Adithan C
Fundam Clin Pharmacol; 2012 Apr; 26(2):295-306. PubMed ID: 21265876
[TBL] [Abstract][Full Text] [Related]
14. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
15. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B; Crettol S; Jaquenoud Sirot E; Bochud M; Ansermot N; Eap CB
Pharmacogenet Genomics; 2009 Nov; 19(11):877-83. PubMed ID: 19801957
[TBL] [Abstract][Full Text] [Related]
16. Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine's Blood Levels and Doses among Jordanian Kidney Transplanted Patients.
El-Shair S; Al Shhab M; Zayed K; Alsmady M; Zihlif M
Curr Drug Metab; 2019; 20(8):682-694. PubMed ID: 31385766
[TBL] [Abstract][Full Text] [Related]
17. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2010 Jul; 11():111. PubMed ID: 20630055
[TBL] [Abstract][Full Text] [Related]
19. CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility.
Kristiansen W; Haugen TB; Witczak O; Andersen JM; Fosså SD; Aschim EL
Int J Androl; 2011 Feb; 34(1):77-83. PubMed ID: 20345875
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5*3 and MDR-1 C3435T single nucleotide polymorphisms in six Chinese ethnic groups.
Lai Y; Zhang J; Wang YX; Wang XD; Li JL; Wang YH; Zeng YJ; Huang M
Pharmazie; 2011 Feb; 66(2):136-40. PubMed ID: 21434577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
